Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Macrogenics (MGNX) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Macrogenics (MGNX) over the last 14 years, with Q3 2025 value amounting to $44.5 million.

  • Macrogenics' Total Current Liabilities fell 2501.98% to $44.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.5 million, marking a year-over-year decrease of 2501.98%. This contributed to the annual value of $55.5 million for FY2024, which is 103.02% down from last year.
  • According to the latest figures from Q3 2025, Macrogenics' Total Current Liabilities is $44.5 million, which was down 2501.98% from $39.0 million recorded in Q2 2025.
  • In the past 5 years, Macrogenics' Total Current Liabilities ranged from a high of $74.6 million in Q4 2021 and a low of $39.0 million during Q2 2025
  • In the last 5 years, Macrogenics' Total Current Liabilities had a median value of $55.4 million in 2025 and averaged $55.2 million.
  • In the last 5 years, Macrogenics' Total Current Liabilities skyrocketed by 5235.98% in 2021 and then crashed by 3481.86% in 2022.
  • Quarter analysis of 5 years shows Macrogenics' Total Current Liabilities stood at $74.6 million in 2021, then plummeted by 34.82% to $48.6 million in 2022, then grew by 15.42% to $56.1 million in 2023, then fell by 1.03% to $55.5 million in 2024, then decreased by 19.92% to $44.5 million in 2025.
  • Its Total Current Liabilities stands at $44.5 million for Q3 2025, versus $39.0 million for Q2 2025 and $55.4 million for Q1 2025.